San Francisco, California, Sept 01, 2017: A new market study by TMR Research states that the global market for sick sinus syndrome treatment has been undergoing a phase of significant growth and is projected to continue on this path over the next few years. The research report, titled “Sick Sinus Syndrome Treatment Market – Global Industry Analysis, Size, Share, Trends, Analysis, Growth, and Forecast 2017–2025,” offers a detailed and unbiased assessment of this market based on its current and historical performance. The trends, driving forces, obstructions, challenges, opportunities, and the future scope of this market have also been thoroughly evaluated while performing this research.
According to the research study, the increasing base of the geriatric population is the key factor behind the growth of the global market for sick sinus syndrome treatment. Apart from this, the rising pediatric population is also propelling this market substantially as children are more susceptible to sick sinus syndrome. Researchers predict these trends to remain boosting this market over the next few years, notes the research study.
The global market for sick sinus syndrome treatments reports its presence across Europe, Asia Pacific (APAC), North America, and the Rest of the World (RoW). Of these, North America leads the overall market with a number of lucrative opportunities as a large portion the population in the U.S. suffers from sick sinus syndrome and opt for the implantation of atrial or dual-chamber pacemakers. The presence of a favorable reimbursement system is another factor that is boosting this regional market significantly.
North America is closely followed by Europe in terms of the potential it holds in the market for sick sinus syndrome treatments. The U.K., Spain, Germany, France, and Italy, have emerged as the prime domestic markets for sick sinus syndrome treatments in Europe, thanks to the burgeoning base of the geriatric population in these years, which is also slated to push this regional market upward in the years to come. The markets in Asia Pacific and the Rest of the World are also projected to record substantial growth on the grounds of the swiftly advancing medical and healthcare infrastructure in emerging economies in this region over the forecast period, states the market report.
The research report also present a competitive analysis of the global marked for sick sinus syndrome treatments. As per the study, Boston Scientific Corp., Medtronic Inc., GlaxoSmithKline, St. Jude Medical Inc., Sorin Group, Biotronik GmbH & Co. KG, Novartis AG, and Pfizer Ltd. are key providers of sick sinus syndrome treatments across the world.
Click on the link below to request a sample copy of the report